Molecules that specifically bind to tumor-associated antigens (TAAs) are crucial for the diagnosis and therapy of cancer. In a recent publication in Molecular Therapy: Oncology, researchers from Université de Nantes presented a novel tailored-made affitin for targeting human mesothelin (hMSLN), which is a TAA overexpressed in many solid cancers and targeted by several experimental drugs.